Loading...
XSHG600538
Market cap338mUSD
Dec 23, Last price  
4.71CNY
1D
-5.61%
1Q
45.37%
Jan 2017
-65.47%
Name

Beihai Gofar Chuanshan Biological Co Ltd

Chart & Performance

D1W1MN
XSHG:600538 chart
P/E
—
P/S
6.69
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
3.54%
Rev. gr., 5y
10.46%
Revenues
369m
-19.69%
373,376,337461,997,669539,191,546789,653,334325,965,913241,318,529363,298,576528,702,660542,982,704452,415,270415,412,217506,408,017455,408,516434,487,818224,523,783251,153,525267,699,833424,717,057459,684,048369,154,644
Net income
0k
-100.00%
16,207,11017,741,58803,035,0710016,403,1460010,688,52704,053,06008,850,64105,772,9383,200,57310,486,53234,841,9800
CFO
-18m
5,940,0142,935,35093,445,47742,598,81717,335,0600000000036,120,2210026,844,78500-17,966,454
Dividend
Jul 09, 20030.1 CNY/sh
Earnings
May 16, 2025

Profile

Beihai Gofar Chuanshan Biological Co., Ltd. engages in the production and distribution of pharmaceutical products in China. The company offers various medicines and medical devices; and produces and sells pearl eyesight eye drops, gastrointestinal granules, pearl powder, and other proprietary Chinese medicines. It also provides molecular medical imaging and tumor radiotherapy centers, as well as tumor telemedicine technical services. The company was formerly known as Beihai Gofar Marine Biological Industry Co., Ltd. and changed its name to Beihai Gofar Chuanshan Biological Co., Ltd. in May 2021. Beihai Gofar Chuanshan Biological Co., Ltd. was founded in 1993 is based in Beihai, China.
URL
http://www.gofar.com.cn/
IPO date
Jan 14, 2003
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
369,155
-19.69%
459,684
8.23%
424,717
58.65%
Cost of revenue
330,058
391,815
379,819
Unusual Expense (Income)
NOPBT
39,097
67,869
44,898
NOPBT Margin
10.59%
14.76%
10.57%
Operating Taxes
3,594
5,445
5,862
Tax Rate
9.19%
8.02%
13.06%
NOPAT
35,503
62,424
39,036
Net income
34,842
232.25%
10,487
227.65%
Dividends
(16)
Dividend yield
0.00%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
7,341
11,670
3,891
Long-term debt
11,010
5,706
5,132
Deferred revenue
Other long-term liabilities
1
Net debt
(270,968)
(338,136)
(347,296)
Cash flow
Cash from operating activities
(17,966)
CAPEX
(10,034)
Cash from investing activities
7,734
Cash from financing activities
5,338
6,623
63,976
FCF
33,734
20,130
(63,784)
Balance
Cash
155,261
170,858
190,403
Long term investments
134,057
184,654
165,916
Excess cash
270,860
332,528
335,083
Stockholders' equity
61,529
581,521
579,017
Invested Capital
830,621
633,557
588,295
ROIC
4.85%
10.22%
6.84%
ROCE
4.37%
7.02%
4.86%
EV
Common stock shares outstanding
514,427
524,198
524,198
Price
4.63
2.43%
4.52
-25.17%
6.04
2.37%
Market cap
2,381,796
0.52%
2,369,377
-25.17%
3,166,158
4.86%
EV
2,120,895
2,039,655
2,824,773
EBITDA
54,849
83,944
60,653
EV/EBITDA
38.67
24.30
46.57
Interest
452
505
528
Interest/NOPBT
1.16%
0.74%
1.18%